Prometic Life Sciences - die bessere Genta?

Sehr geehrte LeserInnen,

mit diesem Thread möchte ich die Aufmerksamkeit auf eine kanadische Biotech-Schmiede lenken, welche

1. ein hervorragendes Netz an Partnern aufweisen kann
2. relativ unbeschadet aus der Krise hervorgehen konnte (siehe Quartalsberichte),
3. meines Erachtens um Längen stabiler und seriöser ist als z.B. Genta,
4. Produkte wie PBI 1402 in der Pipeline hat, die allesamt sehr vielversprechend sind und einen riesigen Markt ansprechen,
und 5. bereits Incomes aufweisen kann (durch Herstellung und Lizenzierung von z. B. P-Capt®).
Alles nachzulesen auf der Unternehmenswebsite  www.prometic.com/
Hinzu kommt der aktuell noch(?) wirklich günstige (Einstiegs-) Kurs, falls wirklich ernsthaft der Ankauf einer  Position in Betracht kommt.

Obwohl die Chancen für Prometic eigentlich gut stehen, gibt es aber weder genug handelbare Aktien in D (siehe Volumen=fast nicht existent) und damit verbunden auch nicht genügend Handelsplätze.
Ich bitte aus diesem Grund um eine rege Beteiligung in diesem Forum und hoffe auf viele wertvolle Beiträge, die die Chancen und das Risiko dieses Papiers, den Handelsmöglichkeiten desselben und generell bereits gemachte Erfahrungen mit Prometic näher beleuchten.

P.S. Meine Aussagen sind keine als Kauf- oder Verkaufsempfehlung und folgende Aussagen von mir in diesem Forum dürfen nicht als solche betrachtet werden.  

oder ist es  nur der briefkurs?  

Hallo Speckulazius.
Unter anderem beschäftigt mich genau diese Frage auch. Der Geldkurs wird ja von denjenigen bestimmt, die die Nachfrage stellen. Und wenn du dir das Angebot bzw. den Briefkurs ansiehst, gibt es so gut wie keine nennenswerten Zahlen - Aber so wie es scheint immer nur einen Anbieter (bei den Stückzahlen). Dazwischen ein riesiger Spread und die Wertermittlung nicht wirklich an die US-Daten bzw. CAN gekoppelt sondern an unsere nichtssagenden zwei Handelsplätze. Die Frage ist warum? Das Angebot ist anscheinend vorhanden, aber es werden immer nur ganz kleine Pakete angeboten und der Preis dadurch künstlich über dem in Übersee gehalten. Ich kann nur für mich selber sprechen und weiß, dass ich Interesse an einer Position dieser Aktie habe. Aber solange für mich nicht geklärt ist, warum das Volumen so gering ist und wer kursbestimmend hinter den Angeboten in FFM steckt (müsst ihr mal beobachten; manchmal tut sich wochenlang nichts am Briefkurs bzw. an den Stückzahlen), werde ich noch kein Angebot meinerseits stellen. Manchmal habe ich das Gefühl, da will jemand nur locken, was ja eigentlich im Grunde genommen einen negativen Beigeschmack auslöst. Jedoch stehen dem gegenüber wirklich gute bis ziemlich gute Kursaussichten. Deswegen nochmals die Bitte um Meinungen und Analysen zu Prometic. Je vielfältiger, desto besser.
LG, oki-wan  

Bei Prometic ist es sehr verwunderlich, dass der Kurs um die 14-15 $-Cent herumdümpelt obwohl alle Anzeichen für einen raketenhaften Aufstieg vorhanden sind. oki-wan's Eröffnungspost hat die wichtigsten Punkte umrissen, doch geht dieser Post für die faulen unter uns am allerwertesten vorbei, da er die Details ungenügend hervorhebt. Deshalb dieser Post mit etwas mehr Substanz, als Appetitanreger für diejenigen, denen Prometic weitgehend unbekannt ist. Keine Kauf- oder Verkaufsempfehlung!

1. )
Prometic ist der einzige (!) Hersteller einer Technologie, welche infektuöse Prionen - also die Verursacher der Creutzfeld-Jakob-Krankheit und damit auch "Rinderwahnsinn" - aus Blut und Blutbestandteilen herausfiltert! Die Technologie heisst "P-Capt" und in GB wurde am 20. November 2009 dem Gesundheitsministerium empfohlen, den Einsatz von "P-Capt" bei allen Blut- und Blutplasmaspenden vorzuschreiben - den Anfang soll die Filtration von Blutspenden ausmachen, die für Kinder mit Geburtsadtum ab 1.1.1996 bestimmt ist.
Quelle: www.prometic.com/en/protein-technologies/prion-capture.php

Der letzte Stand in dieser Sache ist, dass das entsprechende Gesetz am 21. Januar 2010 im House of Lords um die entsprechende Passage erweitert wurde und nun im House of Commons weiterbearbeitet wird:

Point 2 - subsection (3)

The Secretary of State shall also by regulations establish a system to ensure that "the blood supply is made safe through the implementation of prion filtration and that" all blood donors are routinely tested for the conditions listed in subsection (2)

Subsequent to the ratification of this amendment, the Bill was passed at the House of Lords and will now continue its Parliamentary progress in the House of Commons.

Quelle: http://www.prometic.com/en/news-events/...become-legal-582.php?y=2010

2.)
Neben "P-Capt" ist Prometic auch in anderen Bioseparations-Technologien weit vorangeschritten. Hier müssen vor allem zwei erwähnt werden, die zweifelsohne weltweit Abnehmer finden werden.

a) "Mimetic Ligand Technology" und "MAbsorbent ligands": Das erste ist eine Plattform, eine Basis, die entsprechend den Bedürfnissen der Kunden im Separations- und Reinigungsverfahren für alle "targeted proteins" anwendbar ist. Das letztere reinigt bzw. veredelt monoklonale Antikörper ("MAbs") und rekombinante Antikörper Fragmente ("Fabs"). "MAbsorbent" wird in der Veredelung und Verfeinerung von pharmazeutischen Wirkstoffen Anwendung finden und jene durch diesen Prozess in ihrer Wirksamkeit verstärken. Der weltweite Markt für Produkte dieser Technologien überschreitet 16 MRD US-$.

Quelle: http://www.prometic.com/en/protein-technologies/bioseparation.php

b)  "PPPS - Plasma Protein Purification System" : Wie der Name schon sagt, eine Methode um effizient und vollständig Proteine aus dem menschlichen Blutplasma zu extrahieren und zu reinigen bzw. zu veredeln. Wendet Prometics "Mimetic Ligand" -Technologie an. Unter den Lizenznehmern von "PPPS" befindet CNBG, der größte Produzent an Impfstoffen und  Blutderivaten in China. Damit hat Prometic in Süd-Ost-/ Asien einen Fuss in der Tür zu einem der am schnellsten wachsenden Märkte weltweit.

Quelle: http://www.prometic.com/en/protein-technologies/plasma-derived.php

3.)
Aber der wahre Blockbuster Prometics könnte sich hinter der nichtssagenden Bezeichnung PBI-1402 verstecken, einem Mittel gegen Anämie (Blutarmut) im Allgemeinen, sowohl bei Krebspatienten im Rahmen einer Chemotherapie als auch bei Patienten mit anderer Vorgeschichte. Hierzu möchte ich jedoch einen wichtigen Teil direkt von der Prometic-Homepage übernehmen:

ProMetic’s lead candidate drug, PBI-1402, addresses substantial unmet medical needs.

   * PBI-1402 is orally active, whereas most other drugs treating anemia are injectables.
   * PBI-1402 has shown anticancer activity in multiple pre-clinical models.
   * PBI-1402, all the while mimicking EPO’s biological activity, has a distinct mechanism of action from EPO, as it does not bind to the same cell surface receptor as EPO. It therefore provides great promise of serving as a stand-alone therapeutic in the treatment of patients with anemia.
   * PBI-1402 is an affordable low molecular weight synthetic candidate drug, relative to costly recombinant proteins, such as EPO.
   * PBI-1402 addresses a worldwide marketplace that exceeds $15 billion.

Quelle: http://www.prometic.com/en/therapeutics/anemia-PBI-1402.php

PBI-1402 zählt genauso wie PBI-1393, PBI-0110, PBI-1737, PBI-1668 und PBI-1522 zu den  sogenanten "New Chemical Entities - NCEs", auch "Multi-Drug Candidates" genannt. Anwendungsgebiete dieser NCEs sind verschiedene Krebsarten und Autoimmunkrankheiten. Hier auch nochmal ein kleiner Auszug:

Several NCEs identified by ProMetic’s scientists offer numerous possibilities for additional indications and market segments. Additionally, ProMetic’s drug discovery platform has led to the development of numerous compounds for the treatment of cancer and autoimmune diseases. Compounds such as PBI-1393, PBI-0110, PBI-1737, PBI-1668, and PBI-1522 have all demonstrated very impressive activity in various cancer models and represent real drug candidate potential. Additionally, most of these compounds are orally active and preclinical in vivo results seem to indicate that they could be used in combination with standard treatment protocols, such as lowered dosages of chemotherapy, thus resulting in a reduction of associated side-effects such as anemia and / or neutropenia. PBI-1393 and PBI-0110 are in position to enter clinical trials in 2008 subject to corporate strategy. Furthermore, PBI-1737 has evidenced strong results in several different autoimmune and anti-inflammatory models, including simulations of colitis (Irritable Bowel Syndrome, Crohn’s disease) and Multiple Sclerosis. PBI-1308 is a synthetic compound that has been partnered with Darier for further development in the fields of atopic dermatitis and psoriasis. The continued development of the analogues of PBI-1402, and the NCEs signify a family of candidate therapeutics. The implication is far-reaching.

Quelle: http://www.prometic.com/en/therapeutics/hematology-oncology-nces.php

So, das war's erstmal für den Anfang. Beim nächsten Posting gehe ich mal auf die besondere Rolle einiger, aber vor allem eines Partners von Prometic ein.

Beste Grüße an die Leser und eine verheissungsvolle Börsenwoche...  

Heute möchte ich auf eine ganz spezielle Pressemitteilung von Prometic näher eingehen. Sie ist vom 30. April 2009, also fast ein ganzes Jahr alt und behandelt, aber nichtsdestotrotz von schlagender Brisanz.
Hier die gesamte Mitteilung:

------ Sumitomo to act as advisor to ProMetic for Japanese market -------


MONTREAL, QUEBEC, CANADA, AND NEW YORK, NEW YORK, USA - April 30, 2009 - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") and Sumitomo Corporation of America ("SCOA") announces that it has retained the services of SCOA and Summit Pharmaceuticals International ("SPI"), both wholly owned subsidiaries of Sumitomo Corporation ("Sumitomo") to advise ProMetic in its business development activities relating to PBI-1402 for the Japanese market.

In the course of ProMetic's partnering activities several Japanese companies have signaled their interest in PBI-1402.  Consequently, ProMetic has retained the services of Sumitomo to capitalize on this asset. Sumitomo's reach and experience in various commercial fields will facilitate the leveraging of PBI-1402's value for this market.

"Sumitomo is pleased to advise and support ProMetic's activities that aim to increase PBI-1402's reach into the high-return environment of the Japanese market," said Mr. Yasunori Ishibashi, Senior Director of SCOA's Life Science Unit.  "There is increasing demand in Japan for therapeutic drugs such as PBI-1402 that would treat anemia problems associated with cancer treatment and kidney disease.  Our agreement with ProMetic allows them to access the global network and business development services of Sumitomo, while at the same time giving us an option for further investment down the road," states Mr. Ishibashi.

According to Mr. Masahiro Sasaki, President of SPI, "We believe that PBI-1402, with its novel mechanism of action, will become a promising drug for the treatment of anemia associated with cancer and kidney diseases.  The need for such indication is high in Japan as well. We look forward to assisting ProMetic in choosing an appropriate partner for this compound, making the best of the abundant experiences and network of SPI."

Quelle: http://www.prometic.com/en/news-events/...sor-prometic-540.php?y=2009
--------

Jetzt muss man erst einmal etwas zur Sumitomo Corp. sagen:
Sumitomo ist einer der gröten horizontal ausgerichteten japanischen "Keiretsu", d.h. ein Zusammenschluss von Unternehmen aus verschiedenen Branchen (wir würden Mischkonzern sagen). Ein vertikaler Keiretsu wäre z.B. ein Zusammenschluss aus Endhersteller und Zuliefererunternehmen.
Hervorgegangen sind die ersten aus den "Zaibatsu", die 1945 verboten wurden. Oftmals sind sie stark konservativ (man denke an die Samurai und das feudale Japan), was sich auch in ihrem Geschäftsgebaren widerspiegelt:
   * Präsidententreffen zur Absprache von Unternehmensstrategien,
   * eine „Hausbank“, die in der Regel der Hauptkreditgeber ist,
   * ein Generalhandelshaus, das für den Handel im In- und Ausland beauftragt wird,
   * das Überkreuzhalten von Aktien anderer Gruppenmitglieder,
   * das Vorziehen der Vergabe von Aufträgen innerhalb der Gruppe,
   * die Entsendung von Managern in die Vorstände anderer Gruppenunternehmen, sowie
   * ein starkes Zugehörigkeitsgefühl.
(aus Wikipedia, Keiretsu)

Also ziemlich verschlossen bzw. eine elitäre Gruppe, die niemals in risikoreiche Bereiche investiert!
Wenn nun die Pressemeitteilung von Prometic nochmals gelesen wird, wird einem schlagartig vor Augen geführt, welche Bedeutung diese scheinbar kleine Partnerschaft hat!

"Sumitomo ist an der Vermarktung von PBI-1402 interessiert" -
zwischen den Zeilen gelesen heisst das für mich: ... ist von PBI-1402 überzeugt!!!!

Das war's wieder für heut...
Viel Spass beim weiterrecherchieren und Gruss,
TheOracleX  

May 5, 2010 10:30 am
   Annual and Special Meeting of ProMetic Shareholders
   Montreal, Quebec
   ProMetic will host its Annual and Special Meeting of Shareholders on Wednesday, May 5, 2010, at 10:30 (EDT) in the auditorium located on the fourth floor of the Montreal Stock Exchange Tower, 800 Victoria Square in Montreal. For those who are unable to attend the Meeting in person, ProMetic offers a live telephone or audio webcast accessible using the following dial-in information - (416) 800-1066 (international) and 1 (886) 212-9072 (toll free) or through ProMetic's website using the link below. A replay of the event will be available on ProMetic's website following the Meeting.
Webcast: http://www.meetview.com/prometic20100505/

best regards, TheOracleX  

ich gebe es zu: ich habe mich hier nur wegen prometic registriert. find's gut daß hier endlich schwung in die sache kommt.
hasta luego  

morgen ist ein wichtiger tag für prometic. hoffentlich gibts endlich mal DIE bahnbrechende news. wenn interesse besteht -> kauft in übersee an der TSX (toronto), zeichen für proemtic ist PLI. erstens sind sie da günstiger, zweitens gibts da volumen und drittens werden mm die aktien in einem jahr weit über 1$ stehen!!!

keine kaufempfehlung leute, nur eine zusammenfassung meiner erfahrungen (seit 2 monaten in prometics culo verliebt),
butcho  

von der homepage. hört sich ganz gut an; kurs steht in can unverändert auf 0,14 CAN$!

 

Press Releases

 

ProMetic provides guidance for 2010 at its Annual and Special Meeting of Shareholders

MONTREAL, QUEBEC, CANADA - May 5, 2010 - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") reports on financial guidance for 2010 provided during its Annual and Special Meeting of Shareholders (the "Meeting") held on May 5, 2010.

During the Meeting revised guidance was given regarding the Company's estimated financial projections for 2010, indicating that Full Year revenues are anticipated to be in the range of $20.0 million, resulting in an expected net loss for the Full Year 2010 of $5.6 million, equivalent to $0.02 per share.

EBITDA, a non-Canadian GAAP measure which is employed by the Company to measure its performance, is expected to be $(2.9) million for the Full Year 2010. 

Revisions have been made to guidance taking into account the strengthening of the Canadian Dollar against the British Pound.  The majority of revenues are generated in British Pounds but converted to Canadian Dollars as part of the financial reporting process.  Anticipated British Pound revenues remain unchanged since the previous guidance.  There will be a similar impact on costs incurred in British Pounds and this, coupled with ongoing cost control, allows the Company to retain its earnings guidance for the year.

In addition to guidance for the Full Year, the Company also provided guidance in relation to the First Quarter and First Half 2010.  The table below summarizes these figures.

First Qtr. 2010 (Est.)	Half Year 2010 (Est.)	Full Year 2010 (Est.)
Revenues	3,100	8,100	20,000
Net Loss	3,100	4,900	5,600
Net Loss per share (basic and diluted)	0.01	0.02	0.02
EBITDA*	(2,400)	(3,500)	(2,900)

The Company also provided long-range guidance with regards to revenue relating to its Protein Technologies business showing that annual sales could reach between $80 million to $130 million in 2014, depending on the level of adoption of the P-Capt® filter in the United-Kingdom and Ireland. Once again, this revenue guidance excludes possible revenue from the Therapeutics Division.

 

schaut euch bei der meldung den letzten satz an. ich sag nur: echt interessant

Once again, this revenue guidance excludes possible revenue from the Therapeutics Division.  

Guten Abend an die stillen Prometic-Fans und hallo butcho.
HIer ist der Link zur Präsentation, die auf dem Meeting gezeigt wurde:

www.prometic.com/docs/events/117.2010-05-05_ProMetic_AGM_EN_FINAL.pdf

Da sind nochmal einige wirklich nette Sachen dabei, auf die ich morgen näher eingehen werde.
Ausserdem muss ich ja sagen: ich bin echt froh, nicht der einzige in diesem thread zu sein.
Eine geruhsame Nacht wünscht euch
TheOracleX  

Seit Monaten warte ich auf eine gute Kaufgelegenheit,habe mich nur noch nicht getraut.
Die Frage die sich mir stellt ist folgende.Warum derart wenig Leute dieses Papier auf der Rechnung haben?
Anhand der von Ihnen zur Verfügung gestellten Infos kann man erahnen welches Potential dieser Wert entfalten kann!
Für mich persönlich ist aber viel wichtiger,welcher Preis ist realistisch?Denn der Spread hier in Deutschland ist wirklich.....!
Bei diesem Wert sehe ich eine gute Chance mit relativ geringem Einsatz und Zeit,an einer Erfolgsstory teilzunehmen die sich jeder Aktionär wünscht!
----Keine Kaufempfehlung!!!!!Der Handel mit Aktien ist riskant und kann zum Totalverlust führen!!!------  

... Auch aus meiner Sicht einer der Werte mit riesigem Potential! Warte zur Zeit ebenfalls noch auf eine gute Kaufgelegenheit. Wo siehst du die Dr. Watson? Denke zwischen 0.08$ und 0.1$ müsste eigentlich gekauft werden... Fundamentals der Unternehmung sind spitze!! Ein längerfristiges investment wird sich sicherlich schön auszahlen...

Kaufen - zurücklehnen und zusehen wäre dann wohl die Devise... ;)

es grüsst
der Schweizer --rstud--  

So sehe ich das auch!Gemessen an dem was im Erfolgsfall möglich ist?!?!
Der perfekte Zeitpunkt ist immer so eine Sache für sich.Hatte oft richtig gelegen aber genau so oft nicht!
Wenn das Verhältnis zwischen potent. Verlust zu potent. Gewinn stimmt und man seinen Einsatz auch verkraften kann bei nicht Erfolg, ist Timing einfach Glückssache!(Die Region die du angedacht hast schwebt mir auch vor)

Es ist einfach gesagt ein Rissiko das in Kombination mit Erfolg/Glück/Zeit seinen Lohn bringen könnte!
Und dieses Wissen das es nur zwei Möglichkeiten gibt, treibt mich immer wieder auf genau diese Werte:-)
Die Fundamentals versprechen viel, nur habe ich das auf anderen Werten eben auch schon gedacht!
Aber ich bin bei Gelegenheit hier def. mit an Bord!

----Keine Kaufempfelung!!!!!------Nur meine persönliche Meinung  

...

Aus meiner Sicht sind folgende Punkte extrem interessant:

1. Management:
Viel wird Aktien (z.B. Explorer) auf die Namen der Boardmember geachtet. Allerdings ist dies noch lange kein Garant für eine effektive gute Führung! Wenns aber ein Mgt schafft in diesem masse die Kosten zu regulieren ist dies def. ein Leistungsausweis. Habe selber ein BBA und ein MBA, allerdings muss dies nichts heissen. Da hatte es Typen im Studium, in welche ich niiiieeemals investieren würde. :) :)

2. Produkte
Im Gegensatz zu vielen anderen Biotechs ist prometic bereits operativ tätig und hat schon div. Plattformentwicklungen auf dem Markt. Bei einem allfälligen Konkurs könnten diese verwertet werden. -> Risikominimierung!

3. Partner wie Abraxis, red cross, novartis, pfizer usw. sprechen für sich!!http://www.prometic.com/en/prometic/partners.php

Zusammengefasst: Grosses Potential, Risiko für Totalverlust nat KEINE KAFEMPFEHLUNG, WIEDERSPIEGELT DIE MEINUNG DES AUTORS! KEINE AUFFORDERUNG ZUM KAUF <--


ES grüsst aus der CH
rstud  

Liebe Prometic-Mitstreiter,

ich freue mich, dass dieser Thread seit meinem Ableben als oki-wan stetig mehr Beachtung gefunden hat.
Und ja, aus diesem Grund war ich heute auch in Spendierlaune (Sterne) und nochmals ja,
bevor der Aufschrei der Ariva-Mods beginnt (oder auch irgendwelcher Mitleser):
Ich habe mich bzw. mein Alter Ego heute positiv bewertet! Jawohl. Denn ich finde alleion das Thema um Prometic nach wie vor extrem reizvoll und wünsche mir, dass wir hier noch zusammen wahre Sternstunden erleben. Im übrigen bin ich jetzt stolzer Besitzer Prometic-Shares; in Übersee geordert.
In diesem Sinne: TOI, TOI, TOI - werde mich nach der WaMu-Story wieder verstärkt um Prometic kümmern.

...und auch hier ist die Macht mit uns, Oki-Wan 2.0  

 

Hallo zusammen...

Leider benötigt WaMu im Moment einiges an Aufmerksamkeit meinerseits. Deshalb ist Prometic ein wenig untergegangen... Auf jedenfall haben wir Einkaufskurse geshen, welche aus meiner Sicht durchaus für eine erste Postitionierung genutzt werden konnte. Bin folglich dabei...

Was ich eigentlich fragen wollte:
- Wer kann sich das grosse Volumen des letzten Kaufs am Freitag erklären (Anstieg auf 0.105 CAD)? Ob da jemand mehr weiss und eine solche Summe direkt aus dem ASK kauft?

Mal schauen was die nächsten Tage so geschieht...

Liebe Gr WIE IMMER: KEINE KAUF / VERKAUFEMPFEHLUNG, SONDERN NUR DIE MEINUNG DES AUTORS <--  

Weiss jemand, wieso das Volumen plötzlich verzehnfacht hat?

Wollen tatsächlich grosse Player rein? Oder wohl doch ein Sell-Off
Kurs bewegt sich allerdings nicht...

Grüsse
rstudent  

geselle mich hier mal dazu!

Nachdem ich jetzt bei Genta raus bin hört sich dies doch vielversprechend an!

Weiss einer von Euch ob hier ein Splitt oder eine KE ansteht??  

Hallo liebe Mitstreiter.

Ich war lange Zeit im Ausland und hatte keine Gelegenheit mich hier aktiv zu beteiligen. Doch wie ich sehe, dümpelt unsere PLI immer noch in seichten Gewässern... Sehr schade, denn wir wissen alle, welches Potenzial nach wie vor in PLI steckt. Daran hat sich hier in der Zwischenzeit auch nichts geändert. Ich arbeite überdies an einer neuen Bewertung von Prometic und werde diese sobald sie fertig ist auch hier reinstellen. Doch nun erst einmal einige positive Quartalszahlen und -berichte.  Wie immer nachzulesen auf

http://www.prometic.com/en/news-events/press-release-prometic-reports-its-second-quarter-616.php

ProMetic reports its second quarter 2010 financial results

• Year-to-date Protein Technologies business posts a profit of $0.5 million versus losses of $1.8 million for the same period in 2009
• Revenues at $5.1 million for the second quarter of 2010 compared to $2.3 million for the same period last year
• Second quarter 2010 net loss of $0.9 million versus net loss of $5.1 million for the same period 2009
• Year-to-date revenues increase to $8.3 million compared to $6.2 million at June 2009
• Year-to-date loss reduced to $4.1 million compared to $7.1 million at June 2009

MONTREAL, QUEBEC, CANADA - August 10, 2010 - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") today reports its financial results for the second quarter of 2010.  All amounts are in Canadian Dollars unless otherwise indicated.

The following information should be read in conjunction with the financial statements for the second quarter ending June 30, 2010, as well as the Management's Discussion and Analysis for the same period.

Mr. Bruce Pritchard, the Company's Chief Financial Officer commented: "During the second quarter of 2010, the Company has continued to focus on performing against its revenue guidance of $8.1 million for the first half of 2010, issued at the Annual General Meeting of the Shareholders in May.  In that respect, it met and exceeded those targets".  He went on to add: "Management is focused on delivering deals from both the Plasma-Derived Therapeutics business and from its pipeline of other therapeutic products in the second half.  Every effort is being made to ensure that earnings targets for full-year 2010 are met".

"Significant advances were also made with our therapeutics both from a scientific and business development standpoint," stated Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer. Mr. Laurin further indicated: "Management reiterates its confidence in executing on partnering deals which would enable the continuation of the PBI-1402 clinical development programs in anemia and oncology as well as the development of new drug candidates targeting fibrosis and autoimmune diseases".

Highlights

Protein Technologies

• $8.9 million delivery of Mimetic Ligand^TM product - During the first half of 2010, ProMetic delivered on the largest order for a single Mimetic Ligand^TM product worth approximately $8.9 million.
   
• Wuhan Institute for Biological Products program - The WIBP project is progressing according to schedule.  After the successful completion of the initial technology transfer stage earlier this year, ProMetic's scientists have initiated the second technology transfer stage and, over the next quarter, are moving ahead with the retrofit of WIBP's GMP pilot facility.  ProMetic's proprietary Plasma Protein Purification System ("PPPS^TM") will be integrated in WIBP's facility as part of this retrofit.       
  
  Initiation of the scale-up activities for the manufacturing of the first GMP products for the Chinese market are expected in second quarter of 2011.  WIBP will then pursue regulatory approval from the Chinese State Food and Drug Administration ("SFDA") for these products manufactured under licence using ProMetic's proprietary protein technologies, by demonstrating their bioequivalence to commercialized products.  
   
• Instituto de Tecnologia do Paraná of Brazil - Due to various government-related, fiscal and administrative matters, the project with the Instituto de Tecnologia do Paraná of Brazil had encountered some unforeseen delays.  Following various exchanges and attempts to rectify the situation, ProMetic and Tecpar mutually agreed to terminate the license and development agreement late in the second quarter of 2010.  
   
• Advancement on other Protein Technologies Programs - During the first half of 2010, ProMetic has moved forward on the development of several plasma-derived therapeutics. Several milestones were achieved for various programs, enabling these to move to their next respective phases of development.

Therapeutics

• ProMetic presented data on its orally-active PBI-1402 compound at the 15th Congress of the European Hematology Association held in Barcelona, Spain, June 9 - 13, 2010. Clinical and preclinical results were presented about the management of side effects induced by chemotherapy and the treatment of certain cancers such as lung and pancreatic cancers, and certain forms of leukemia.      
  
  In addition, an oral presentation was made regarding the positive clinical data generated in patients that developed anemia as a result of their chemotherapy. The clinical trial demonstrated a reduction in the need for blood transfusions in chemotherapy-induced anemic patients. Furthermore, the trial data indicated that the level of hemoglobin and red blood cells never exceeded recommended levels even when the drug was used at high dose. This, combined with anti-cancer activity demonstrated in numerous cancer models, supports the potential use of PBI-1402 to address unmet medical needs in oncology.
   
• The PBI-1402 development program also led to the discovery of new and proprietary chemical compounds (NCEs) that regulate fibrosis via a novel mechanism of action.  Fibrosis is part of the inflammatory process that leads to a loss of functionality in vital organs such as kidney, heart, liver and lungs in certain chronic diseases that affects hundreds of millions of patients.  These first-in-class NCEs are orally active, and have been confirmed to exhibit strong anti-fibrotic activity in various in vivo models.
   
• Further advances were also accomplished with the Company's portfolio of autoimmune disease drug candidates.
   
• These advances improve the Company's ability to finalize partnering deals that will aim at pursuing the PBI-1402 clinical development programs in anemia and oncology as well as the development of new drug candidates targeting fibrosis and autoimmune diseases.

Second Quarter 2010

The second quarter of 2010 was again a busy one for the business with generated revenues amounting to $5.1 million compared to $2.3 million for the same period last year.   It is worth reminding readers again that the revenues of the business do not accrue in a straight line during the year, and that anticipated revenues are geared towards the latter quarters in the Company's plan.  During the same period, the Protein Technologies Business unit posted a profit of $1.4 million compared to a loss of $2.1 million in 2009.  This performance allowed the entire group to reach an EBITDA breakeven in the second quarter of 2010.

Operating costs for the quarter were down to $5.6 million from $6.7 million in the same quarter of the previous year.  This decrease was mainly attributable to the Research and Development tax credits and to the reduced impact of foreign exchange costs and reduced amortization costs. 

The debt on the balance sheet consists of loans from long-term shareholders and strategic business partners.

Analyzing the business segment performance for the quarter highlights the loss associated with the Therapeutics division, relating to strategic R&D spend to assist with business development discussions. Protein Technologies posted a gain due to increased revenues and the resulting gross profit together with a reduction in R&D costs. Corporate losses reduced due to exchange rate variances.

Profit (Loss) *	Q2 2010	Q2 2009	Change %
Therapeutics	(510)	(425)	20%
Protein Technologies	1,433	(2,074)	(169%)
Corporate	(1,861)	(2,596)	(28%)
Total Loss	(938)	(5,096)	(82%)

* in thousands of dollars

ProMetic's MD&A and 2010 Second Quarter Financial Statements have been filed on Sedar (http://www.sedar.com/) and are available on the Company's web site at http://www.prometic.com/.

About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. ("ProMetic") (http://www.prometic.com/) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand^TM technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montréal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and Canada, manufacturing facilities in the U.K. and business development activities in the US, Europe, Asia and in the Middle-East.

Forward Looking Statements
This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 24 of ProMetic's Annual Information Form for the year ended December 31, 2009, under the heading "Risk and Uncertainties related to ProMetic's business".  As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.  All amounts are in Canadian dollars unless indicated otherwise.

 

Mit besten Grüßen

TheOracleX

 

 

Einen schönen guten Abend wünsche ich den hier anwesenden Mitstreitern.
Ich bin zwar mit meiner angekündigten neuen Bewertung noch nicht fertig,
jedoch ereilte mich diese E-Mail vielversprechenden Inhalts zur Zukunft Prometics.
Wir dürften alle noch positiv überrascht werden...
Ciao
----------------------------------------

01-09-2010 | PROMETIC LIFE SCIENCES INC.
Information regarding activities of interest to ProMetic/ Octapharma has successfully completed their prion depleted Uniplas® clinical development and filed for European approval

BY E-MAIL

ProMetic would like to bring to your attention a new release from Octapharma AG titled "Uniplas® Clinical Development Successfully Completed".  This release can also be accessed through our Information of Interest web page: http://www.prometic.com/en/prometic/information.php.

Uniplas®, is a novel, blood group independent, universally applicable, solvent/detergent treated, human pooled plasma for infusion, that was prion-depleted using ProMetic's pathogen reduction technology platform. Uniplas® can be given to all patients irrespective of their blood group, thus abolishing the risks and serious consequences that can result from a transfusion of an incompatible plasma unit.  Trials also demonstrated that adding prion depletion did not otherwise change Uniplas®'s profile.

Octapharma has filed for registration of Uniplas® in Europe and will submit later in the USA.

Additional Documentation

2010-08-27 Uniplas Clinical Development  

http://www.prometic.com/en/news-events/...captr-filter-620.php?y=2010

DoH urged to adopt P-Capt(R) filter to safeguard transfusion blood as new HPA research indicates up to 40,000 people in the UK may harbour vCJD prion - News comes as Macau begins routine prion filtration of donated blood with P-Capt(R)

MONTREAL, QUEBEC, CANADA AND LILLE, FRANCE - October 13, 2010 - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") and MacoPharma SA ("MacoPharma"). In the light of new research findings published by the Health Protection Agency ("HPA")+ that 1 in 9160 tonsil samples tested showed evidence of variant Creutzfeldt-Jakob disease ("vCJD"), ProMetic and MacoPharma strongly recommend the UK Department of Health ("DoH") implement the CE marked P-Capt® prion reduction filter as a matter of urgency to safeguard the UK blood supply. The HPA results suggest that up to 40,000 people in the UK (which equates to the population of a medium sized town) may be incubating vCJD without knowing it and could pass it on when they donate blood.

‘This latest research highlights the ongoing threat of prion diseases and the need to filter transfusion blood to ensure that donors who are carrying latent prions do not infect recipients' commented Ms. Iwona Walicka, Project Manager of MacoPharma SA, which manufactures and distributes the filter. ‘P-Capt® has been extensively and independently tested for three years: it works (99.9% or greater of vCJD reduction efficacy), it's safe, effective for a wide range of prion proteins and its implementation has been recommended by an independent UK Safety committee. We urge the DoH to begin using P-Capt® now, before more people are infected with these lethal agents.'

‘The HPA research confirms the threat to human health posed by prions remains very real' added Dr. Steve Burton, Chief Executive Officer of ProMetic BioSciences Ltd, who developed the prion binding material used in the P-Capt® filter in collaboration with the American Red Cross and leading U.S. academics. ‘There continue to be deaths from vCJD and a few weeks ago researchers from Case Western Reserve University in the U.S. identified a new human prion brain disease, similar to vCJD, which is associated with a fast-advancing form of dementia. It is now nearly a year since the UK's Advisory Committee on the Safety of Blood, Tissues and Organs ("SaBTO"), recommended the DoH adopt the P-Capt® filter and it is important that this crucial safeguard against transmissible prion diseases is implemented without further delay".

The HPA report comes at a time when the Macau Blood Transfusion Service has started to use P-Capt® to remove vCJD from red blood cell concentrates ("RBCC") donated by Caucasians at risk of carrying the prion. Macau is a region of China which is close to Hong Kong and home to about half a million inhabitants including a small expatriate community.

‘So far 4 people worldwide have contracted vCJD from blood transfusions and 1 haemophiliac from clotting factor concentrates derived from plasma and we know that 31 individuals who contracted and died of vCJD were blood donors' said Ms Walicka. ‘The incidence of vCJD is greatest in the UK and since prion infectivity can lie dormant for decades before the disease develops, we simply do not know how widespread the disease could become.'

In the UK, four years after P-Capt® was CE mark approved, prion filtration has still not been implemented despite a recommendation from SaBTO to adopt the filter to pre-treat red blood cells destined for children born since 1 January 1996. SaBTO made this recommendation in November 2009 but the DoH has not commented on the implementation of P-Capt® since then. In Ireland, P-Capt® is being used routinely in one pilot hospital and is currently undergoing a health technology assessment (due to be completed by the end of 2010) in relation to national policy and adoption. Meanwhile, in the UK, according to the leaked ‘Quangos at Risk' register it appears that SaBTO, the HPA and the Spongiform Encephalopathy Advisory Committee (SEAC), three groups that focus on vCJD and blood safety, could soon be disbanded.

* vCJD is a devastating disease for which there is no cure.

* P-Capt® has been extensively and independently tested for three years by all the UK Blood Services, the Irish National Blood Transfusion Service and the Health Protection Agency. The filter binds all prions tested to date.

* 1.8 million blood units are donated in England each year.

* At present UK donated red blood cell concentrates are leucodepleted which is not sufficient to prevent vCJD prion infectivity.

* Full implementation to filter all donated blood would cost around a pound per person in England (population 51 million).

* Since 1996 there have been 174 cases of vCJD in the UK of whom 170 have died (Source: The National CJD Surveillance Unit Figures October 4, 2010).

* In June 2009 SaBTO recommended that all plasma from UK blood donors be disposed of due to the vCJD risk and today the UK imports its plasma, largely from the U.S.  

http://www.prometic.com/en/news-events/...ic-agreement-622.php?y=2010

ProMetic signs terms of strategic agreement for PBI-1402 and PBI-4419 with Allist Pharmaceuticals of China

   * Allist to fund and accelerate the development programs for PBI-1402 and PBI-4419

   * Allist secures exclusive commercial rights for the Chinese market

   * ProMetic retains rights to data for other markets, representing savings of over US $10M in future development costs;

   * PBI-1402 clinical development will be further advanced for chemotherapy-induced anemia and cancer related anemia indications

   * PBI-4419 will be developed for fibrotic disease indications

   * Agreement includes US$ 59 M in milestone payments to ProMetic as well as royalties on sales in China

MONTREAL, QUEBEC, CANADA - SHANGHAI, CHINA - October 18, 2010 - ProMetic Life Sciences Inc. (TSX: PLI) ("ProMetic") and Allist Pharmaceuticals, Inc. ("Allist") announced today that they have entered into a strategic agreement to develop and commercialize ProMetic's drug candidates PBI-1402 and PBI-4419 in China. This agreement strengthens ProMetic's development plan for these assets in other markets.

Allist will fund the development costs required for the regulatory approval in China for the two products. As part of the conditions for the rights granted, Allist undertakes to perform development activities according to standards meeting FDA requirements, which will then allow ProMetic to have full access to and use the data generated by Allist for markets outside China.  This represents an investment in the programs well in excess of US$10 M.  Allist will retain the rights for the Chinese market for PBI-1402 for the chemotherapy-induced anemia ("CIA") and cancer related anemia ("CRA") indications and for PBI-4419 for fibrotic diseases.

"We are very excited about this strategic relationship as it capitalizes on our respective companies' strengths," stated Dr. Jianhui Guo, Chief Executive Officer of Allist.  "ProMetic's research & development program has generated very promising First-in-Class drugs to address unmet medical needs and Allist will accelerate the development of these two drug candidates.  Our developmental capabilities provide for a natural, complementary and strategic fit with ProMetic."

Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer commented: "This enabling agreement is perfectly aligned with ProMetic's development strategy for its Therapeutics business unit: (1) It leverages the synergies and the investment made by Allist in the development program in that we can use this critical data for other lucrative markets; (2) It enables us to accelerate the development of these valuable drug candidates on a cash neutral basis; and (3) It provides ProMetic with a solid partner for the ever-expanding Chinese market, expected to become the 4th largest domestic pharmaceutical market by 2013."

In addition to the funding commitments and the execution of the development program, Allist has agreed to pay ProMetic performance milestones totaling US$59 M and royalties on future products sales.  Upon ProMetic completing a technology transfer for the two drug candidates this quarter, Allist will proceed with the scale-up of the manufacturing processes and will initiate clinical trials as well as other pivotal development activities.

"Allist is one of the few pharmaceutical companies in China focused on developing innovative therapeutics as opposed to generic drugs," stated Dr. Tom Chen, ProMetic's Vice-President Product and Asia Pacific Development. "Allist is very well funded and will soon have capacity to produce over 250 metric tons of pharmaceutical bulk active drugs.  Allist is not only a solid partner to develop and commercialize the products in China, but this relationship strengthens ProMetic's position outside China with expanded manufacturing capabilities.  For instance, ProMetic will have the option to access large supply manufacturing capacity for PBI-1402 and PBI-4419 for markets outside China," added Dr. Chen.

ProMetic and Allist will finalize and execute definitive documentation and relevant development work plans regarding this strategic agreement within sixty (60) days from the date hereof.

More on PBI-1402 and PBI-4419
PBI-1402 is a first-in-class, orally active, non-EPO receptor erythropoietic regulating agent ("ERA"), which offers significant advantages in the treatment of anemia in cancer patients.  With proven anti-cancer activity and no risk to bring red blood cells or hemoglobin to unsafe levels, PBI-1402 offers the potential to become the safest drug to treat anemia in cancer patients.  In a phase Ib/IIa clinical trial performed in patients suffering of anemia induced by chemotherapy, 93% of patients did not require blood transfusion.  PBI-4419 is a first-in-class, orally active, more potent third generation analogue of PBI-1402. PBI-4419 is ProMetic's lead candidate drug in development for the treatment of various inflammatory and fibrosis conditions.

About Allist Pharmaceuticals, Inc.
Allist Pharmaceuticals, Inc. (http://www.allist.com.cn/allist_en/) is engaged in discovery, development and commercialization of novel pharmaceutical products for human health. The mission of the company is to be a leading innovator of therapeutic drugs devoted to human health and human life worldwide.

Founded in May of 2004, Allist's Research and Development Center is located in Zhangjiang Hi-tech Park, Shanghai and is focused on new chemical entities and drug delivery systems in the fields of cardiovascular diseases, acid-related diseases and cancers.

At present, taking advantage of a rapidly growing Chinese biomedical and pharmaceutical industry, Allist pushes forward with developing technology and improving human health strategies to realize its goals of becoming one of the leaders in the global pharmaceutical industry.

About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (http://www.prometic.com/) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic LigandTM technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology, cancer, inflammation and fibrosis. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montréal (Canada), ProMetic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and business development activities in the U.S., Europe, Asia and in the Middle-East.  

http://www.prometic.com/en/news-events/...hird-quarter-627.php?y=2010

ProMetic reports its third quarter 2010 financial results

   * Allist Pharmaceuticals injects $10 Million in the immediate development of PBI-1402 and PBI-4419 and fully funds the clinical and regulatory development of both drugs for the Chinese market
   * Stage set for transformational strategic agreements to positively impact the Company
   * In spite of lower than expected revenue, adjusted net loss demonstrates improvement in business units' performance in 2010 YTD vs. 2009 YTD

MONTREAL, QUEBEC, CANADA - November 15, 2010 - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") today reports its financial results for the third quarter of 2010.  All amounts are in Canadian Dollars unless otherwise indicated.

The following information should be read in conjunction with the financial statements for the third quarter ending September 30, 2010, as well as the Management's Discussion and Analysis for the same period.

"During the third quarter, Management was involved in a significant amount of Corporate and business development activities, setting the stage for a pipeline of transformational strategic agreements to impact positively the Company" stated Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer.  Mr. Laurin continued: "This includes the first deal involving PBI-4419, one of the recently discovered follow-on analogues of PBI-1402.  ProMetic's development program has created potent new drugs targeting significant opportunities for unmet medical needs in the fibrosis market."

Specifically, through this agreement Allist is to fund and accelerate the development programs for PBI-1402 and PBI-4419, in return for exclusive commercial rights for the Chinese market.  ProMetic retains rights to the data for other markets, representing savings of over US $10M in future development costs.  In relation to the clinical programs, PBI-1402 clinical development will be further advanced for chemotherapy-induced anemia and cancer related anemia indications and PBI-4419 will be developed for fibrotic disease indications.  The agreement includes US$ 59 M in milestone payments to ProMetic as well as royalties on sales in China.

Mr. Bruce Pritchard, the Company's Chief Financial Officer commented: "The third quarter of 2010 was a busy one for the business, with much effort going into the business development activities on all fronts.  The results for the Year-to-date, when compared to the adjusted results for Year-to-date 2009 which remove the extraordinary gains, show a significant improvement in the business' performance. However, regulatory delays for Octapharma, one of our key customers, have meant that they have delayed their originally anticipated orders for the second half of this year into 2011.  This will impact ProMetic's revenue forecast for the second half."  Mr. Pritchard stated: "In light of this, efforts continue with cost control so that the cash runway can be stretched."

Mr. Laurin went on to add: "All other business units of ProMetic are engaged in a number of discussions regarding potential strategic agreements that we expect will confirm value and provide cash to the group."

Third Quarter 2010
The third quarter of 2010 was characterized by lower than expected revenues associated with the bioseparations business. Revenues from one of ProMetic's key customers, Octapharma AG ("Octapharma"), were delayed as a result of certain issues on their side, with these issues impacting ProMetic's revenue for the third & fourth quarters of 2010 compared to forecast.

Adjusting the 2009 Year-to-date results to remove the impact of the extra-ordinary gains relating to foreign exchange and the acquisition of the majority share in PRDT demonstrates more clearly the improvement in business performance for the Year-to-date 2010, as summarized in the table below.

                         2010       2009      Improvement
YTD Revenue     10,317    9,300       11%

YTD Net Loss       4,847    7,740       60%
"Adjusted"

Net Loss %      47%        83%

* in thousands of dollars

Octapharma has informed ProMetic that it is close to finalizing the approval process for its OctaplasLG® product in additional EU countries. OctaplasLG® is Octapharma's prion-depleted, solvent/detergent treated and pharmaceutically licensed plasma. The product is already approved for use in Germany and Switzerland, as well as in Australia. The UK's regulator (Medicines and Healthcare products Regulatory Agency "MHRA"), which is acting as rapporteur under the mutual recognition process for the approval in other EU member states, will resume their approval process in November 2010 after an additional requested study has been successfully completed by the Octapharma researchers and submitted.

This delay has a number of impacts for ProMetic, stemming from Octapharma not yet ordering its originally estimated volumes of prion reduction resin in the latter part of this financial year. In particular, this will impact second half revenues by around GBP 2.6 Million (approximately CAD $4 Million). In addition to the reduction in revenues, the expected offset of the advance from Octapharma, which sits on the balance sheet of ProMetic, will be diminished. This advance is repayable against ongoing resin orders. As a result, the overall balance will remain higher than anticipated, however, due to profile of sales, the majority of the balance will appear as a long-term rather than a short-term creditor.

Octapharma remains positive regarding the ultimate regulatory approval of its OctaplasLG® product by the MHRA and its ultimate approval in additional key EU countries, we therefore expect orders for resin to recommence in 2011. Furthermore, Octapharma also announced recently that it is seeking regulatory approval for a prion-depleted version of its UniplasLG® product, which will also rely on ProMetic's prion reduction technology.

Offsetting this, continued development of plasma-derived therapeutics products for customers, such as Abraxis BioScience, delivered revenues to the top-line.  As a result of all this, revenues for the quarter amounted to $2.1 Million compared to $3.1 Million for the same period in 2009.

Operating costs for the quarter were up to $4.5 Million from $3.5 Million in the same quarter of the previous year.  This increase was attributable to exchange rate movements. In general, all other operating costs were in line with those incurred in the third quarter of 2009.

The debt on the balance sheet consists of loans from long-term shareholders and strategic business partners. Discussions are already advancing with these lenders to reschedule the repayment of these loans, to assist further with minimizing the cash requirements for 2011.

Revision to Financial Guidance and impact on cash runway
At the Annual General Meeting in May 2010, guidance was provided indicating EBITDA and Net Loss of approximately $(3) Million and $(6) Million respectively, which was used as a benchmark for cash requirement.

In light of the confirmation from Octapharma, regarding the delay to their predicted resin orders for the latter part of 2010, the Company is revising its financial guidance for 2010. As outlined, the impact of the delay to the Octapharma order is approximately $4 Million to the top line.  As a result, revenue guidance is being reduced.  This will have an impact on both EBITDA and Net loss which are now expected to be approximately $(6) Million and $(8) Million respectively.

This reduction in forecast revenue is outside the control of ProMetic, and has been confirmed by Octapharma as a delay and not a cancellation in the order.  With this in mind, the Company is confident that these revenues will occur in 2011.

Throughout the year, Management has emphasized in the MD&A the importance of its actions to modulate costs, enabling it as far as possible to maintain its EBITDA guidance, and as a result has been able to lessen the impact of this revenue reduction on its cash runway.

Nevertheless, the increase in the net loss attributable to 2010 has had an inevitable impact on the cash reserves.  At this stage, the Company is still confident that it can manage its cash runway into the first quarter of 2011, and is actively working on business development activities and additional non-dilutive financing projects.

ProMetic's MD&A and 2010 Third Quarter Financial Statements have been filed on Sedar (http://www.sedar.com/) and are available on the Company's web site at http://www.prometic.com/.